EMIT IMAGING Announces Appointment of Dr. Matthew Silva as Chief Executive Officer
EMIT IMAGING, Inc. ("EMIT" or the "Company") is pleased to announce the appointment of Dr. Matthew Silva as the company's new Chief Executive Officer.
EMIT IMAGING is the world leader in Cryo-Fluorescence Tomography (CFT) imaging, an innovative imaging technology used by pharmaceutical, biotechnology, and academic researchers worldwide. EMIT's imaging platform, XerraTM, is a state-of-the-art technology that provides high-sensitivity and high-resolution 3D fluorescence images of biological samples.
Dr. Silva brings diverse experience and expertise in both science and business to the role, specifically drawing on technical training in biomedical engineering and previous executive positions in pharma and scientific services. Recently, Dr. Silva served as CEO of Invicro, LLC, an imaging contract research organization and subsidiary of REALM IDx/Konica Minolta.
"We are thrilled to have Dr. Silva join the EMIT team," said Dr. Jack Hoppi, EMIT's founder and Chairman of the Board. "Matt has the greatest breadth and depth of understanding across imaging modalities and applications of anyone I have ever worked with. Combining this knowledge and perspective with his proven track record of driving growth and innovation make him the perfect leader to guide EMIT into the future."
Dr. Silva added, "I am honored to join the company at such an exciting time. I look forward to working with the talented team at EMIT IMAGING to continue delivering innovative solutions that improve research. I am particularly excited about the opportunity to expand the use of CFT and the Xerra imaging system in the pharmaceutical and biotechnology industries."
About EMIT IMAGING
EMIT IMAGING is the leader of Cryo-Fluorescence Tomography (CFT) imaging and is pioneering hardware, software, and data science methods. EMIT's imaging platform, XerraTM, is a state-of-the-art technology that provides high-sensitivity and high-resolution 3D images of biological samples and is used by pharmaceutical, biotechnology, and academic researchers worldwide to advance scientific and medical research. To learn more about EMIT, visit www.emitimaging.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005039/en/